- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Novavax starts first phase 3 COVID-19 vaccine trial in the UK | ||
| Fr | Lilly's Verzenio scores a win in early-stage breast cancer | ||
| Fr | FDA sets January decision date for Xalkori in ALK-positive lymphoma | ||
| Fr | Q&A: Isabel Gibson | ||
| Fr | Pearls of wisdom | ||
| Do | UK COVID-19 vaccine 'challenge trials' could intentionally infect participants with virus | ||
| Do | Keytruda doubles five-year survival rate in NSCLC | ||
| Do | EMA fast-tracks review of bluebird bio's LentiGlobin for sickle cell disease | ||
| Do | Surviving cancer: a new era for patients | ||
| Mi | FDA hands BMS and bluebird bio a priority review for ide-cel | ||
| Mi | Janssen's EGFR-targeting treatment regimen shows early benefit in lung cancer | ||
| Mi | Relief Therapeutics seeks US emergency approval for COVID-19 drug | ||
| Mi | Could formulary intelligence be your brand differentiator? | ||
| Mi | How COVID-19 is accelerating the threat of antimicrobial resistance | ||
| Di | New restrictions announced as UK's COVID-19 alert level is increased | ||
| Di | Keytruda plus chemotherapy cuts risk of death by 27% in advanced oesophageal cancer | ||
| Di | AZ/Merck's Lynparza improves survival in certain prostate cancers | ||
| Di | The flexible salesforce | ||
| Di | Navigating engagement and remote working during the pandemic | ||
| 21.09. | AZ's Tagrisso cuts risk of EGFR-positive NSCLC spreading to the brain | ||
| 21.09. | BMS eyes approval for second Opdivo combo in kidney cancer | ||
| 21.09. | Pfizer's ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial | ||
| 18.09. | BioNTech bolsters COVID-19 vaccine capacity with Novartis deal | ||
| 18.09. | Moderna inks R&D agreements with Vertex and Chiesi | ||
| 17.09. | Eli Lilly reports first results for COVID-19 targeting antibody |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
